home · filing · 0001104659-23-130516
8-K filed December 29, 2023, 6:59 PM ET
ticker IMNM
CIK 0001472012
leadership
confidence high
sentiment neutral
materiality 0.60
Immunome CFO Corleen Roche departs; Max Rosett named Interim CFO; Bob Lapetina named principal accounting officer
Immunome Inc.
CFO Corleen Roche separates effective Jan 2, 2024; receives 10.5 months salary continuation, $75,000 cash, COBRA coverage, and one-year option exercise extension.
Roche to provide consulting from Jan 2 to Apr 5, 2024 at $300/hour; equity continues vesting during consulting period.
Max Rosett appointed Interim CFO and principal financial officer; he has served as SVP Operations since Oct 2023.
Bob Lapetina appointed principal accounting officer; is VP Finance & Corp Controller since May 2021; eligible for two $15,000 retention bonuses through 2024.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2024-01-02
Filed December 29, 2023, 6:59 PM ET
appointed Bob Lapetina, in addition to his other titles, as the Company’s principal accounting officer.
Effective 2024-01-02
Filed December 29, 2023, 6:59 PM ET
appointed Max Rosett, in addition to his other titles, as the Company’s Interim Chief Financial Officer and principal financial officer.
Departed
Corleen Roche
Chief Financial Officer
Effective 2024-01-02
Successor Max Rosett
Filed December 29, 2023, 6:59 PM ET
Ms. Roche will no longer serve as the Company’s Chief Financial Officer, principal financial officer or principal accounting officer.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Bob Lapetina was appointed as Principal Accounting Officer at Immunome Inc..
Action appointed
Role Principal Accounting Officer
Exact text from the filing
appointed Bob Lapetina, in addition to his other titles, as the Company’s principal accounting officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Max Rosett was appointed as Interim Chief Financial Officer at Immunome Inc..
Action appointed
Role Interim Chief Financial Officer
Exact text from the filing
appointed Max Rosett, in addition to his other titles, as the Company’s Interim Chief Financial Officer and principal financial officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Corleen Roche departed as Chief Financial Officer at Immunome Inc..
Action agreed to a mutual separation
Role Chief Financial Officer
Exact text from the filing
Ms. Roche will no longer serve as the Company’s Chief Financial Officer, principal financial officer or principal accounting officer.
View on SEC.gov
Source: SEC EDGAR
accession 0001104659-23-130516
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.